Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory‑approved products to meet the needs of eye‑care professionals across multiple regions.

Monoprost (latanoprost) is a prostaglandin analog used to reduce intra‑ocular pressure in glaucoma‑related conditions.

Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Secondary open-angle glaucoma: decreases pressure when other causes elevate intra‑ocular pressure.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash growth. - Darkening of the iris pigment. - Mild eye irritation or foreign‑body sensation. - Blurred vision. - Temporary eye discomfort.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash). - Uveitis or intra‑ocular inflammation. - Corneal edema or swelling. - Paradoxical increase in intra‑ocular pressure. - Vision loss. - Persistent eye pain.

Before using Monoprost, consider the following precautions: - Monitor intra‑ocular pressure regularly during treatment. - Avoid use in eyes with active infection or inflammation. - Use with caution in patients with a history of uveitis. - Advise patients not to wear contact lenses while using the drops. - Discuss pregnancy or breastfeeding status with the prescriber. - Store at room temperature: keep the bottle in the original packaging, protect from light and avoid freezing.

Monoprost may interact with other ocular medications. Review the following:

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops. - Simultaneous administration of ocular anesthetics that may increase irritation.

Moderate Interactions (Monitor Closely):\n- Beta‑blocker eye drops (additive IOP‑lowering effect). - Alpha‑agonist eye drops (potential additive pressure reduction). - Topical corticosteroids (may diminish prostaglandin efficacy). - Systemic antihistamines (possible impact on tear production). - Ocular lubricants (generally safe but monitor for discomfort).